Curasight: Q3 confirmed - the company is on track from a medical advancement perspective.
Curasight: Q3 confirmed - the company is on track from a medical advancement perspective
Danish based biotech company Curasight released their 3rd quarter report last week which confirmed the company is on track from a medical advancement perspective as the company continues to make progress with its so called theranostic concept to combine diagnose and treatment of various forms of cancer. Still in their developing phase, Curasight reported zero revenue and a loss before tax of DKK 8,5 million and a loss of DKK 25,3 million for the first three quarters of 2023 as the company develops its pipeline of uTRACE and uTREAT product candidates for diagnosing and treating different forms of cancer types. Cash position remains strong with a cash position of DKK 27,7 million.
Investors has grown accustomed to witnessing Curasight publish encouraging new preclinical or clinical data to support an ongoing expansion of new types of cancer forms to be diagnosed and treated. Recently, the latest example was the announcement of positive preclinical data of uTREAT for non-small cell lung cancer. What has become more interesting, however, is the announcement of partner deals that validates both uTREAT and uTRACE as concepts – but also supports the company’s funding situation. To illustrate, the share price of Curasight doubled in the weeks after the first – and so far only - of such announcements were made in the beginning of May of 2023, when Curasight entered a partnership arrangement with Curium to accelerate Curasight’s development of uTRACE for prostate cancer. Since then, Curasight has continued to develop its pipeline, but no new partnerships have been announced, and although the Curasight share price is up more than 60 percent this year making it one of the best biotech investments, investors have seen the share price drop 35 percent from its peak in May when news of the deal was released.
Investors eager to learn more about Curasight and its theranostic concept, as well as hearing more of the prospect and potential for new partnership deals can join the HCA event on Wednesday, November 29th where CEO Ulrich Krasilnikoff and CSO and co-founder Andreas Kjær will present the 3rd quarter report and take questions. Please sign up here: Q3 event Curasight
Disclaimer: HC Andersen Capital receives payment from Curasight for a Digital IR/Corporate Visibility subscription agreement. /Claus Thestrup 8:30 AM 27-11-2023.
Curasight is a Danish biotech company focusing on developing and improving the detection and treatment of cancer in a more gentle and efficient way. The company has two pipeline products that both use radionuclide (nuclear medicine) to facilitate better diagnosis and treatment of various cancer types; uTRACE use the so-called uPAR as a biomarker to diagnose the aggressiveness of cancer, and uTREAT use the uPAR as a attachment to treat the cancer. Based on good phase 2 data that has already been collected or will be in the first half of 2022, Curasight is expected to prepare phase 3 for uTRACE later in 2022 and 2023 for the following four cancer types: prostate, brain, neuroendocrine, and head and neck cancer.
Read more on company page
